Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-170X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial ; volume:28 ; number:9 ; day:8 ; month:8 ; year:2022 ; pages:1840-1847 ; date:9.2022
Nature medicine ; 28, Heft 9 (8.8.2022), 1840-1847, 9.2022
- Creator
-
Bartsch, Rupert
Bergmeister-Berghoff, Anna Sophie
Furtner, Julia
Marhold, Maximilian
Bergen, Elisabeth Sophie
Roider-Schur, Sophie
Starzer, Angelika Martina
Forstner, Heidrun
Rottenmanner, Beate
Dieckmann, Karin
Bago-Horvath, Zsuzsanna
Haslacher, Helmuth
Widhalm, Georg
Ilhan-Mutlu, Aysegül
Minichsdorfer, Christoph
Fuereder, Thorsten
Szekeres, Thomas
Oehler, Leopold
Gruenberger, Birgit
Singer, Christian F.
Weltermann, Ansgar
Puhr, Rainer
Preusser, Matthias
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-022-01935-8
- URN
-
urn:nbn:de:101:1-2022120921245200236314
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bartsch, Rupert
- Bergmeister-Berghoff, Anna Sophie
- Furtner, Julia
- Marhold, Maximilian
- Bergen, Elisabeth Sophie
- Roider-Schur, Sophie
- Starzer, Angelika Martina
- Forstner, Heidrun
- Rottenmanner, Beate
- Dieckmann, Karin
- Bago-Horvath, Zsuzsanna
- Haslacher, Helmuth
- Widhalm, Georg
- Ilhan-Mutlu, Aysegül
- Minichsdorfer, Christoph
- Fuereder, Thorsten
- Szekeres, Thomas
- Oehler, Leopold
- Gruenberger, Birgit
- Singer, Christian F.
- Weltermann, Ansgar
- Puhr, Rainer
- Preusser, Matthias
- SpringerLink (Online service)
Other Objects (12)
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial